Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Silver Nanoparticles Targets Tumors

By BiotechDaily International staff writers
Posted on 17 Jun 2014
Print article
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Scientists have devised a nanoparticle that has a couple of unique, and key, characteristics. Spherical in shape and made up of silver, it is encased in a shell coated with a peptide that enables it to target tumor cells. Moreover, the shell is etchable, therefore, those nanoparticles that do not hit their target can be broken down and eliminated.

The research findings were published June 8, 2014, in the journal Nature Materials. The core of the nanoparticle employs a feature known as plasmonics. In plasmonics, nanostructured metals such as silver and gold resonate in light and concentrate the electromagnetic field near the surface. In this manner, fluorescent dyes are enhanced, appearing about 10 times brighter than their natural state when no metal is present. When the core is etched, the enhancement retreats and the particle becomes dim.

University of California-Santa Barbara’s (UCSB; USA) Ruoslahti Research Laboratory also developed a simple etching technique using biocompatible chemicals to quickly disassemble and take away the silver nanoparticles outside living cells. This method leaves only the intact nanoparticles for imaging or quantification, thus revealing which cells have been targeted and how much each cell internalized.

“The disassembly is an interesting concept for creating drugs that respond to a certain stimulus,” said Gary Braun, a postdoctoral associate in the Ruoslahti Lab in the department of molecular, cellular and developmental biology (MCDB) and at Sanford-Burnham Medical Research Institute. “It also minimizes the off-target toxicity by breaking down the excess nanoparticles so they can then be cleared through the kidneys.”

This method for removing nanoparticles unable to penetrate target cells is unique. “By focusing on the nanoparticles that actually got into cells,” Dr. Braun said, “we can then understand which cells were targeted and study the tissue transport pathways in more detail.”

Various agents are able to pass through the cell membrane by themselves, but many drugs, particularly RNA and DNA genetic drugs, are charged molecules that are stopped by the membrane. These drugs must be taken in through endocytosis, the process by which cells absorb molecules by surrounding them. “This typically requires a nanoparticle carrier to protect the drug and carry it into the cell,” Dr. Braun said. “And that’s what we measured: the internalization of a carrier via endocytosis.”

Because the nanoparticle has a core shell structure, the researchers can vary its exterior coating and compare the efficiency of tumor targeting and internalization. Switching out the surface agent enables the targeting of different diseases—or organisms in the case of bacteria—through the use of different target receptors. According to Dr. Braun, this should become a strategy to optimize drug delivery where the core is a drug-containing vehicle.

“These new nanoparticles have some remarkable properties that have already proven useful as a tool in our work that relates to targeted drug delivery into tumors,” said Erkki Ruoslahti, adjunct distinguished professor in UCSB’s Center for Nanomedicine and MCDB department and at Sanford-Burnham Medical Research Institute. “They also have potential applications in combating infections. Dangerous infections caused by bacteria that are resistant to all antibiotics are getting more common, and new approaches to deal with this problem are desperately needed. Silver is a locally used antibacterial agent and our targeting technology may make it possible to use silver nanoparticles in treating infections anywhere in the body.”

Related Links:

University of California-Santa Barbara



Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.